<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatrics. Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Pediatrics. Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Педиатрия. Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2658-6630</issn><issn publication-format="electronic">2658-6622</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71109</article-id><article-id pub-id-type="doi">10.26442/26586630.2021.1.200632</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A rational approach to the treatment of urinary tract infections in children</article-title><trans-title-group xml:lang="ru"><trans-title>Рациональный подход к терапии инфекции мочевой системы у детей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1547-0016</contrib-id><name-alternatives><name xml:lang="en"><surname>Chugunova</surname><given-names>Olga L.</given-names></name><name xml:lang="ru"><surname>Чугунова</surname><given-names>Ольга Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. госпитальной педиатрии</p></bio><email>ol_chugunova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2021</year></pub-date><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>63</fpage><lpage>71</lpage><history><date date-type="received" iso-8601-date="2021-05-30"><day>30</day><month>05</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-30"><day>30</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://pediatria.orscience.ru/2658-6630/article/view/71109">https://pediatria.orscience.ru/2658-6630/article/view/71109</self-uri><abstract xml:lang="en"><p>The article discusses the issues of complex therapy of urinary tract infection (UTI) in children on the basis of a discussion of modern features of etiology, pathogenesis, and clinical manifestations. The emergence of microbial biofilms and the increasing resistance of pathogens that cause the development of UTI dictate the need to search for new methods of treatment. To overcome the persistence of bacteria and reinfection, rational antibiotic therapy is required, taking into account the sensitivity of the sown flora to antibiotics, the rejection of the use of long-term antibiotic prophylaxis, the elimination of organic and functional disorders of urodynamics, as well as the use of herbal medicines. If the child does not have severe abnormalities or there is a functional obstruction, then alternative methods should be considered as a preventive anti-relapse measure. After courses of antibiotic and uroseptic, or simultaneously with them, the herbal medicinal product Canephron® N can be prescribed, which contains parts of three plants – the roots of lovage, herb centaury and rosemary leaves. The drug has antimicrobial, anti-inflammatory, antispasmodic and diuretic effects. Its use can increase the effectiveness of complex treatment of exacerbations and preventive therapy for recurrent UTI.</p></abstract><trans-abstract xml:lang="ru"><p>В статье рассматриваются вопросы комплексной терапии инфекции мочевой системы (ИМС) у детей на основании обсуждения современных особенностей этиологии, патогенеза, клинических проявлений. Появление микробных биопленок и увеличивающаяся резистентность возбудителей, вызывающих развитие ИМС, диктует необходимость поиска новых методов лечения. Для преодоления персистенции бактерий и реинфекции необходимы рациональная антибиотикотерапия с учетом чувствительности высеваемой флоры к антибиотикам, отказ от использования длительной антибиотикопрофилактики, устранение органических и функциональных нарушений уродинамики, а также применение лекарственных средств растительного происхождения. Если у ребенка нет тяжелых аномалий или имеет место обструкция функционального характера, то в качестве профилактической противорецидивной меры следует рассматривать альтернативные методы. После курсов антибиотика и уросептика или одновременно с ними может быть назначен растительный лекарственный препарат Канефрон® Н, в состав которого входят части трех растений – корни любистока лекарственного, трава золототысячника и листья розмарина. Препарат оказывает противомикробное, противовоспалительное, спазмолитическое и диуретическое действие. Его применение может повысить эффективность комплексного лечения обострений и профилактической терапии рецидивов ИМС.</p></trans-abstract><kwd-group xml:lang="en"><kwd>urinary tract infection</kwd><kwd>pyelonephritis</kwd><kwd>Canephron N</kwd><kwd>children</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>инфекция мочевой системы</kwd><kwd>пиелонефрит</kwd><kwd>Канефрон Н</kwd><kwd>дети</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Lellig E, Apfelbeck M, Straub J et al. Urinary tract infections in children. Urologe A 2017; 56 (2): 247–62.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Larcombe J. Urinary tract infection in children: recurrent infections. BMJ Clin Evid 2015; 2015.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Зоркин С.Н., Катосова Л.К., Музыченко З.Н. Лечение инфекции мочевыводящих путей у детей. Мед. совет. 2009; 4: 25–30 [Zorkin SN, Katosova LK, Muzychenko ZN. Lechenie infektsii mochevyvodiashchikh putei u detei. Med. sovet. 2009; 4: 25–30 (in Russian)].</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Клинические рекомендации Минздрава России. Профессиональные ассоциации: Союз педиатров России. Инфекция мочевыводящих путей у детей. 2018 [Clinical guidelines of the Russian Ministry of Health. Professional associations: Union of Pediatricians of Russia. Urinary tract infection in children. 2018 (in Russian)].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Чугунова О.Л. Течение инфекции мочевой системы у детей раннего возраста на фоне острой респираторной вирусной инфекции. Эффективная фармакотерапия. 2016; 44: 38–50 [Chugunova OL. Techenie infektsii mochevoi sistemy u detei rannego vozrasta na fone ostroi respiratornoi virusnoi infektsii. Effektivnaia farmakoterapiia. 2016; 44: 38–50 (in Russian)].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sorlózano-Puerto A, Gómez-Luque JM, Luna-Del-Castillo JD, et al. Etiological and Resistance Profile of Bacteria Involved in Urinary Tract Infections in Young Children. Biomed Res Int 2017; 2017: 4909452. DOI: 10.1155/2017/4909452</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Коровина Н.А., Захарова И.Н., Страчунский Л.С., и др. Практические рекомендации по антибактериальной терапии инфекций мочевой системы внебольничного происхождения у детей (пособие для врачей). Клин. микробиология и антимикроб. химиотерапия 2002; 4 (4): 337–46 [Korovina NA, Zakharova IN, Strachunskii LS, et al. Prakticheskie rekomendatsii po antibakterial’noi terapii infektsii mochevoi sistemy vnebol’nichnogo proiskhozhdeniia u detei (posobie dlia vrachei). Klin. mikrobiologiia i antimikrob. khimioterapiia 2002; 4 (4): 337–46 (in Russian)].</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Чугунова О.Л., Шумихина М.В., Думова С.В., Фоктова А.С. Особенности патогенеза, диагностики, течения инфекций органов мочевой системы у новорожденных и детей раннего возраста, возможности терапевтической коррекции. Вестн. соврем. клин. медицины. 2013; 6 (6): 119–28 [Chugunova OL, Shumikhina MV, Dumova SV, Foktova AS. Osobennosti patogeneza, diagnostiki, techeniia infektsii organov mochevoi sistemy u novorozhdennykh i detei rannego vozrasta, vozmozhnosti terapevticheskoi korrektsii. Vestn. sovrem. klin. meditsiny. 2013; 6 (6): 119–28 (in Russian)].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Чугунова О.Л., Шумихина М.В. Инфекция мочевой системы у детей: актуальные вопросы. Эффективная фармакотерапия. Педиатрия. 2015; 3: 10–21 [Chugunova OL, Shumikhina MV. Urinary tract infection in children: current issues. Effective pharmacotherapy. Pediatrics. 2015; 3: 10–21 (in Russian)].</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Shaikh N, Shope TR, Hoberman A, Vigliotti A еt al. Association Between Uropathogen and Pyuria. Pediatrics 2016; 138 (1). DOI: 10.1542/peds.2016-0087</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Brubaker L, Wolfe A. The female uriniary microbiota, urinary health and common urinary disorders. Ann Transl Med 2017; 5 (2): 34.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Amarenco G. Microbiote urinaire et troubles mictionnels. Progrès en urologie 2015; 25: 615–27.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Джакипбекова З.К., Несмеянова Е.П. Применение препаратов Цицибон и Канефрон н в профилактическом лечении инфекции мочевыводящих путей. World science. 2016; 2 (1): 28–32 [Dzhakipbekova ZK, Nesmeianova EP. Primenenie preparatov Tsitsibon i Kanefron n v profilakticheskom lechenii infektsii mochevyvodiashchikh putei. World science. 2016; 2 (1): 28–32 (in Russian)].</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Murugapoopathy V, McCusker C, Gupta IR. The pathogenesis and management of renal scarring in children with vesicoureteral reflux and pyelonephrotis. Ped Nephrol 2020; 35 (3): 349–57. DOI: 10.1007/s00467-018-4187-9</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Mattoo TK, Chesney RW, Greenfield SP, et.al. RIVUR Trial Investigators (2016). Renal scarring in the randomized intervention for children with vesicoureteral reflux (RIVUR) Trial. Clin J Am Soc Nephrol 2016; 11: 54–61. DOI: 10.2215/CJN.05210515</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Deo SS, Vaidya AK. Elevated levels of secretory immunoglobulin A (sIgA) in urinary tract infections. Indian J Pediatr 2004; 71: 37–40.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lee G, Romih R, Zupančič D. Cystitis: from urothelial cell biology to clinical applications. Biomed Res Int 2014; 10. DOI: 10.1155/2014/473536</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Valore EV, Park CH, Quayle AJ, et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101: 1633–42. DOI: 10.1172/JCI1861</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Nielsen KL, Dynesen P, Larsen P, еt al. Role of urinary cathelicidin LL-37 and human b-defensin 1 in uncomplicated Escherichia coli urinary tract infections. Infect Immun 2014; 82: 1572–8. DOI: 10.1128/iai.01393-13</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Watnick P, Kolter R. Biofilm, city of microbes. J Bacteriol 2000; 182: 2675–9.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318–22.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Мальцев С.В., Мансурова Г.Ш. Что такое биопленка? Практическая медицина. 2011; 5 (53): 7–10 [Mal’tsev SV, Mansurova GSh. Chto takoe bioplenka? Prakticheskaia meditsina. 2011; 5 (53): 7–10 (in Russian)].</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hancock V, Ferrieres L, Klemm P. Biofilm formation by asymptomatic and virulent urinary tract infectious Escherichia coli strains. FEMS Immunol Med Microbiol 2007; 51: 212–9.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Серова Г.А., Паунова С.С. Инфекция мочевой системы у детей (обзор литературы). Нефрология и диализ. 2007; 9 (1): 86–91 [Serova GA, Paunova SS. Infektsiia mochevoi sistemy u detei (obzor literatury). Nefrologiia i dializ. 2007; 9 (1): 86–91 (in Russian)].</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Ped Nephrol 2007; 22: 1199–2009.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Bergman DA, Baltz RD, Cooley JR, et al. Practice Parameter: The Diagnosis, Treatment, and Evalution of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Urinary Tract Infection. Pediatrics 1999; 103 (4): 843–52.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Urinary Tract Infection In Children (Diagnosis, Treatment And Long-Term Management). National Collaborating Centre for Women’s and Children’s Health UK. Clinical Guideline. August 2007.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>American Academy of Pediatrics: Section on Urology Response to New Guidelines for the Diagnosis and Management of UTI. Pediatrics. March 2012.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Prat C, Dominguez J, Rodrigo D, et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis J 2003; 22 (5): 438–42.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ольхова Е.Б., Копылова Е.М., Пачес О.А., Никитина С.Ю. Ультразвуковое исследование почек при пузырно-мочеточниковом рефлюксе у детей. Эхография. 2001; 2 (2): 201–11 [Ol’khova EB, Kopylova EM, Paches OA, Nikitina SIu. Ul’trazvukovoe issledovanie pochek pri puzyrno-mochetochnikovom refliukse u detei. Ekhografiia. 2001; 2 (2): 201–11 (in Russian)].</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Tsai J-D, Huang F-Y, Tsai T-C. Asymptomatic vesicoureteral reflux detected by neonatal ultrasonographic screening. Ped Nephrol 1998; 12: 206–9.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Коровина Н.А., Захарова И.Н., Мумладзе Э.Б. Диагностика и лечение пиелонефрита у детей: пособие для врачей. М.: Медпрактика-М, 2007 [Korovina NA, Zakharova IN, Mumladze EB. Diagnostics and treatment of pyelonephritis in children: a guide for doctors. Moscow: Medpraktika-M, 2007 (in Russian)].</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>La Scola C, De Mutiis C, Hewitt IK, et al. Different guidelines for imaging after first UTI in febrile infants: yield, cost, and radiation. Pediatrics 2013; 131 (3): 665–71.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Hoberman A, Charron M, Hickey RW, et al. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348 (2): 195–202.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Hennaut E, Duong HP, Chiodini B, et al. Prospective Cohort Study Investigating the Safety and Efficacy of Ambulatory Treatment With Oral Cefuroxime-Axetil in Febrile Children With Urinary Tract Infection. Front Pediatr 2018; 6: 237.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Piñeiro Pérez R, Cilleruelo Ortega MJ, Ares Álvarez J, et al. Recommendations on the diagnosis and treatment of urinary tract infection. An Pediatr (Barc) 2019; 90 (6): 1–9.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Kaufman J, Temple-Smith M, Sanci L. Urinary tract infections in children: an overview of diagnosis and management. BMJ Paediatr Open 2019; 3 (1): e000487.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Коровина Н.А., Захарова И.Н., Мумладзе Э.Б. Острый цистит у детей: клиника, диагностика, лечение. Лечащий врач. 2003; 7: 63–9 [Korovina NA, Zakharova IN, Mumladze EB. Ostryi tsistit u detei: klinika, diagnostika, lechenie. Lechashchii vrach. 2003; 7: 63–9 (in Russian)].</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Vazouras K, Basmaci R, Bielicki J, et al. Antibiotics and Cure Rates in Childhood Febrile Urinary Tract Infections in Clinical Trials: A Systematic Review and Meta-analysis. Drugs 2018; 78 (15): 1593–604.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Лойман Э., Цыгин А.Н., Саркисян А.А. Детская нефрология. Практическое руководство. М.: Литтерра, 2010 [Loiman E, Tsygin AN, Sarkisyan AA. Pediatric nephrology. A practical guide. Moscow: Litterra, 2010 (in Russian)].</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Calzi A, Grignolo S, Caviglia I, еt al. Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children. Eur J Pediatr 2016; 175 (9): 1219–25. DOI: 10.1007/s00431-016-2763-1</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>DeMuri GP, Wald ER. Imaging and antimicrobial prophylaxis following the diagnosis of urinary tractinfection in children. Pediatr Inf Dis J 2008; 27 (6): 553–4.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>De St Maurice A, Willis Z, Ross S. Antibiotic Stewardship and the Diagnosis of UTI in Children With Neurogenic Bladders. Pediatrics 2018; 142 (2).</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Яковлев С.В. Антибактериальная терапия внебольничных неосложненных инфекций мочевыводящих путей с позиций современного состояния антибиотикорезистентности. РМЖ. 2006; 27: 1998 [Iakovlev SV. Antibakterial’naia terapiia vnebol’nichnykh neoslozhnennykh infektsii mochevyvodiashchikh putei s pozitsii sovremennogo sostoianiia antibiotikorezistentnosti. RMZh. 2006; 27: 1998 (in Russian)].</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Pennesi M, Travan L, Peratoner L, et al. North East Italy Prophylaxis in VUR study group. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. Pediatrics 2008; 121 (6).</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Montini G, Hewitt I. Prophylaxis or no prophylaxis after urinary infection in children? G Ital Nefrol 2009; 26 (4): 420.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Brandstrom P, Hansson S. Long-Term Low-Dose Prophylaxis against Urinary Tract Infections in Young Children. Ped Nephrol 2015; 30: 425–32. DOI: 10.1007/s00467-014-2854-z</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Cai T, Tamanini I, Kulchavenya E, et al. The role of nutraceuticals and phytotherapy in the management of urinary tract infections: What we need to know? Arch Ital Urol Androl 2017; 89 (1): 1–6.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Veauthier B, Miller MV. Urinary Tract Infections in Young Children and Infants: Common Questions and Answers. Am Fam Physician 2020; 102 (5): 278–85.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Чугунова О.Л. Инфекции мочевой системы у детей: что могут комбинированные растительные средства? StatusРraesens. Педиатрия и неонатология. 2019; 4 (62): 64–73 [Chugunova OL. Infektsii mochevoi sistemy u detei: chto mogut kombinirovannye rastitel’nye sredstva? StatusPraesens. Pediatriia i neonatologiia. 2019; 4 (62): 64–73 (in Russian)].</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Fernández-Puentes V, Uberos J, Rodríguez-Belmonte R, et al. Efficacy and safety profile of cranberry in infants and children with recurrent urinary tract infection. An Pediatr (Barc) 2015; 82 (6): 397–403.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Симоновская Х.Ю., Легкий С.В. Технологии и системный подход превращают лечение травами в точную науку. StatusPraesens. Педиатрия и неонатология. 2019; 2 (58): 59–65 [Simonovskaia KhIu, Legkii SV. Tekhnologii i sistemnyi podkhod prevrashchaiut lechenie travami v tochnuiu nauku. StatusPraesens. Pediatriia i neonatologiia. 2019; 2 (58): 59–65 (in Russian)].</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Сафронова Е.С., Соколова Я.С., Лишик И.А., и др. Применение «Канефрона Н» с профилактической целью при беременности с заболеванием мочевыделительной системы (пиелонефрит). Достижения науки и образования. 2019; 5 (46): 98–103 [Safronova ES, Sokolova IaS, Lishik IA, et al. Primenenie «Kanefrona N’ s profilakticheskoi tsel’iu pri beremennosti s zabolevaniem mochevydelitel’noi sistemy (pielonefrit). Dostizheniia nauki i obrazovaniia. 2019; 5 (46): 98–103 (in Russian)].</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Riemann K. Studies carried out in order to collate practical data in accordance with 22 (3) of the German Drug Law (Medicines Act, Gesomed Study 2), Final Report, Internal documentation, Bionorica AG 1990 (unpublished).</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Коровина Н.А., Захарова И.Н. Лечение хронического тубулоинтерстициального нефрита у детей. Педиатрия. Журн. им. Г.Н. Сперанского. 2008; 87 (3): 86–90 [Korovina NA, Zakharova IN. Lechenie khronicheskogo tubulointerstitsial’nogo nefrita u detei. Pediatriia. Zhurn. im. G.N. Speranskogo. 2008; 87 (3): 86–90 (in Russian)].</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Летифов Г.М., Кривоновова Е.П. Место Канефрона Н в комплексной терапии инфекции мочевой системы и дисметаболических нефропатий у детей. Практика педиатра. 2017; 2: 36–40 [Letifov GM, Krivonovova EP. Mesto Kanefrona N v kompleksnoi terapii infektsii mochevoi sistemy i dismetabolicheskikh nefropatii u detei. Praktika pediatra. 2017; 2: 36–40 (in Russian)].</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Эрман М.В. Фитотерапия в лечении инфекции мочевой системы у детей. Эффективная фармакотерапия. 2014; 16: 18–22 [Erman MV. Fitoterapiia v lechenii infektsii mochevoi sistemy u detei. Effektivnaia farmakoterapiia. 2014; 16: 18–22 (in Russian)].</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Иванов Д.Д., Кушниренко С.В. Оценка лечебного и профилактического потенциала препарата канефрон н при острых циститах у детей: результаты клинического исследования. Почки. 2013; 3 (5): 9–13 [Ivanov DD, Kushnirenko SV. Otsenka lechebnogo i profilakticheskogo potentsiala preparata kanefron n pri ostrykh tsistitakh u detei: rezul’taty klinicheskogo issledovaniia. Pochki. 2013; 3 (5): 9–13 (in Russian)].</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Длин В.В., Шатохина О.В., Османов И.М., Юрьева Э.А. Эффективность Канефрона Н у детей с дисметаболической нефропатией с оксалатно-кальциевой кристаллурией. Вестн. педиатрической фармакологии и нутрициологии. 2008; 5 (4): 66–9 [Dlin VV, Shatokhina OV, Osmanov IM, Iur’eva EA. Effektivnost’ Kanefrona N u detei s dismetabolicheskoi nefropatiei s oksalatno-kal’tsievoi kristalluriei. Vestn. pediatricheskoi farmakologii i nutritsiologii. 2008; 5 (4): 66–9 (in Russian)].</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Кириллов В.И., Богданова Н.А. Клинико-патогенетическое обоснование эффективности растительного препарата Канефрон Н в нефрологии детского возраста. РМЖ. 2015; 5: 1–6 [Kirillov VI, Bogdanova NA. Kliniko-patogeneticheskoe obosnovanie effektivnosti rastitel’nogo preparata Kanefron N v nefrologii detskogo vozrasta. RMZh. 2015; 5: 1–6 (in Russian)].</mixed-citation></ref></ref-list></back></article>
